

11th October 2022

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release - Cipla's Indore plant joins the World Economic Forum's (WEF) prestigious Lighthouse Network

Dear Sir / Madam,

Please find enclosed press release dated 11th October 2022 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Encl: as above

Prepared by: Juzer Masta

Cipla's Indore plant joins the World Economic Forum's (WEF) prestigious Lighthouse Network

- Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
- Demonstrates advanced technologies to drive productivity, workforce engagement, sustainability, and resilience across 22 sites in parallel

Mumbai, India; October 11, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) ("Cipla") today announced that its Indore Oral Solid Dosage (OSD) plant has been designated by the World Economic Forum as an 'Advanced Fourth Industrial Revolution (4IR) Lighthouse'. This is the first Cipla facility to receive the coveted recognition. The organisation is amongst the first pharmaceutical companies in India & Asia and one of the few generic pharmaceutical companies in the world to be part of the Global Lighthouse Network.

The Global Lighthouse Network is an exclusive community of manufacturing leaders from across sectors who depict an accelerated adoption of 4IR technologies to transform factories, value chains and business models for resilience, growth and sustainability.

Over the course of two years, Cipla deployed 'Digital Automation Analytics' (DAA) across a network of 22 India sites in parallel to unlock end to end costs, productivity and quality leadership. Cipla's Indore Oral Solid Dosage (OSD) facility led this journey with 30+4IR use cases, spanning Industrial Internet of Things, Digital, Advanced Analytics, Natural Language Processing (NLP), Robotic Process Automation, etc. These revolutionary technologies (along with other classic levers) result in reduced manufacturing cost, greater agility, and speed. The impact generated across multiple fronts at Cipla's Indore Oral Solid Dosage (OSD) facility includes **23%*** rise in productivity, **28%** decrease in specific Greenhouse gas (GHG) emissions and quality enhancement.

Commenting on the back of this development, **Umang Vohra, Managing Director and Global CEO, Cipla** said, "This recognition is a true testament of our steadfast focus towards transforming Cipla into a digitally native future-ready organization. We have embarked on a journey to enhance our connect with patients, doctors & other stakeholders in line with our aspiration to reimagine operations across the value chain. Embedding a digital culture in the organisation enables us to stay ahead of the curve and helps achieve our sustainability pledges whilst increasing operational efficiencies. I would like to thank team Indore for this remarkable demonstration of digital transformation"

Speaking about this, **Geena Malhotra, Global Chief Technology Officer, Cipla** added, "We are redefining benchmarks in pharma by being the early adopters of 4IR technologies at scale. Our digital transformation initiatives are ensuring greater agility, speed, process simplification, higher efficiencies and faster resolution of challenges. It has also aided in integrating sustainability into the core of our manufacturing operations, which is a key enabler of our ESG commitments."

With Cipla deploying 4IR technologies in 22 sites simultaneously, the company has adopted a digital transformation approach that is 'at-scale by design'. Overall, this has supported Cipla's endeavour of pioneering access to high quality affordable drugs globally despite rising challenges of volatility, steep price cuts and growing input costs.

Speaking about the Global Lighthouse Network, **Francisco Betti, Head of Shaping the Future of Advanced Manufacturing and Value Chains, World Economic Forum** said, "Global disruptions have highlighted the fragility of current supply chains – as rising inflation and material shortages are increasing pressure on manufacturing organizations, Lighthouses show that scaling the deployment and adoption of 4IR technologies across multiple factories and business functions is key to accelerate the achievement of their strategic imperatives, such as business growth, resilience and greener operations."

Cipla's Indore facility will be introduced as a new member of the Lighthouse network on 13 October 2022 at 5:30 pm IST at a virtual event that will be livestreamed globally. This will also comprise a discussion with Lighthouse Leaders, which includes Umang Vohra, Managing Director and Global CEO, Cipla, sharing how Cipla is leveraging 4IR tech to transform its operations and shape a more resilient, sustainable, and human-centric future of manufacturing. The event can be accessed on this link: [Lighthouses Live: Shaping the next chapter of the Fourth Industrial Revolution - McKinsey Talks Operations](#)

*** Mn pill / FTE in FY22 (YTD Jan) vs FY20**

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT July'22), 3rd largest in the pharma private market in South Africa (IQVIA MAT July'22), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring forLife' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

About the Global Lighthouse Network:

The Global Lighthouse Network is a community of production sites and value chains that are world leaders in the adoption and integration of the cutting-edge technologies of the Fourth Industrial Revolution (4IR). Lighthouses apply 4IR technologies such as artificial intelligence, 3D-printing and big data analytics to

maximize efficiency and competitiveness at scale, transform business models and drive economic growth, while augmenting the workforce, protecting the environment and contributing to a learning journey for all-sized manufacturers across all geographies and industries. The Global Lighthouse Network is a World Economic Forum project in collaboration with McKinsey & Co, factories and value chains that join the Network are designated by an independent panel of experts.

For queries, please contact:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com